Generic drug market in Central and Eastern Europe jumped to €17.2bn in 2008, accounting for around 58% of the pharmaceutical market in the region in terms of value.
Meanwhile the market value figure for innovative drugs stood at €12.4bn, according to a new report by PMR Publications, a company providing market information, advice and services to international businesses interested in Central and Eastern European countries and other emerging markets.
The CAGR for generics will reach as much as 14% between 2009 and 2011, whereas that of innovative drugs will be much lower.
“As a result, the share of generic drugs will constantly increase and in 2009 generics will account for around 60% of the pharmaceutical market in Central and Eastern Europe”, according to Agnieszka Stawarska, Pharmaceutical Market Analyst at PMR and a co-author of the report.
Although the innovative drug market in Central and Eastern Europe will develop at a slower rate than that of generic drugs between 2009 and 2011, the growth rate of original medicines for the whole region will be positive.
Growth in innovative drug market has been compromised by the cost-containment policies of the CEE countries, which have been stepped up during the global financial crisis.
However, in the medium term predictions are that there will be an improvement in health awareness and the modernisation of healthcare systems, including the development of private health insurance and the establishment of health insurance and drug reimbursement systems, similar to those in European countries, in Russia and Ukraine, to be drivers of the innovative drug market in the CEE countries, the report said.
An additional driver will be the aging of the population in the region.
Innovative pharmaceutical companies of local origin in Central and Eastern Europe are far and few. Most companies based in the region are generic drug manufacturers. The largest players of this kind include Gedeon Richer, Krka, Egis and Zentiva. These companies have a presence in most CEE countries and they are well-established there.
CEE’s second group of companies consists of global generic players. Their presence differs from one CEE country to the next. For example, Dr. Reddy’s, an Indian generic manufacturer, concentrates on Russia, which is one of the company’s key markets worldwide.
Actavis, an Iceland-based manufacturer, is at its strongest in Bulgaria and Russia. Ranbaxy’s key markets in the region are Romania and the CIS countries (Russia and Ukraine in particular).
Stada has a strong presence in Russia, particularly after the acquisition of two Russian companies (Nizhpharm and Makiz-Pharma); and at the beginning of 2009 the company entered Poland and Bulgaria by establishing subsidiaries there.
Consolidation processes recently took place in the generic arena were of great importance for Central and Eastern Europe, according to the report.
For example, Teva gained a strong presence in the region through the acquisition of Barr in July 2008, which included one of the largest local generic drug producers ? the Croatian company Pliva.
Similarly, in June 2008, Mylan, a US generic manufacturer, acquired the CEE generics businesses of Merck KGaA, the prominent German drug manufacturer. The deal includes Merck’s operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic.
In March 2009 Zentiva, one of the leading generic players in the region, was bought by Sanofi-Aventis. In May 2009 Novartis acquired the generic cancer drug production division of the Austria-based EBEWE Pharma.
The innovative drug market in the region is dominated by multinational pharmaceutical companies. Such companies have representative offices in most of the Central and Eastern European countries, but, as they are active all over the world, the region is not, in most cases, their main market.
However, innovative drug producers often choose Central and Eastern Europe as a place in which to locate clinical trials, because of the low costs, high population and limited access to innovative therapies in such countries.